Remove Chemotherapy Remove Hospitals Remove Mayo Clinic
article thumbnail

Chemotherapy prescribing habits for stage 3 colon cancer changed following IDEA study

Hospital Pharmacy Europe

A significant and increasing trend towards the use of a three-month rather than six-month adjuvant chemotherapy regime in stage 3 colon cancer has been observed following publications from the IDEA collaboration abstract. In addition, CAPOX prescribing also significantly increased from 14% to 48% (p <0.001).

article thumbnail

ASH roundup: late breakers take the stage

pharmaphorum

At ASH, the E1910 clinical trial generated results could unlock a new patient population for Blincyto, after it was shown to improve overall survival in patients with no measurable residual disease (MRD) after induction chemotherapy for B-ALL. “It’s a huge step forward for treating this devastating disease.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ondansetron interactions to avoid

The Checkup by Singlecare

Sources Monoamine oxidase inhibitors (MAOIs) , Mayo Clinic (2019). Journal of hospital medicine (2010). The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron , Clinical pharmacology and therapeutics (1999). Mayo Clinic (2022). Phenylketonuria.

article thumbnail

What causes sharp pain on the right side of the body?

The Checkup by Singlecare

According to the CDC , treatment includes surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these treatments. appeared first on The Checkup.

article thumbnail

How can I tell if I have a UTI or yeast infection?

The Checkup by Singlecare

A complicated UTI may require a longer course of antibiotics and may require treatment in the hospital. According to the Mayo Clinic , up to 75% of women will have at least one yeast infection in their lives, with some women experiencing two or more. A kidney infection is an example of a complicated UTI.